drugset / Trial / NCT06122610

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

NCT06122610

Phase 1 Completed 4 enrolled University of Wisconsin, Madison
NaSingle-groupOpen-labelTreatment

Summary

The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans

Timeline

Start
2025-03-07
Primary completion
2026-05-31
Completion
2026-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTATATE Peptide
Subject COPPER OXODOTREOTIDE Peptide